Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
CJC-1295
GH Increase2-3x
Studies4
Participants85
StatusAvailable

CJC-1295

CJC-1295 with DAC (Drug Affinity Complex)

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to stimulate natural growth hormone production from the pituitary gland. Its unique Drug Affinity Complex (DAC) modification allows it to bind to albumin, extending its half-life to 6-8 days and enabling sustained pulsatile growth hormone release. Unlike direct growth hormone therapy, CJC-1295 works with the body's natural rhythms to optimize anabolic effects while maintaining physiological hormone patterns.

Clinical Safety Profile

Reported Side Effects

Injection site reactions (redness, swelling, irritation)
Transient headaches (reported in 10-15% of participants)
Mild flushing episodes (5-10% of users)
Nausea (less common, 3-5%)
Fatigue during initial adjustment period
Dizziness (rare, typically dose-related)
Flu-like symptoms in some individuals
Temporary water retention

Side Effect Management (Clinical Trial Data)

Injection Site Reactions
Common
15.2%
Headaches
Infrequent
8.7%
Flushing
Occasional
12.4%
Fatigue
Infrequent
6.8%
Nausea
Infrequent
4.3%

Side Effect Management Strategies

Nausea: Take with food, smaller meals, ginger supplements
Vomiting: Slower dose escalation, anti-emetics if severe
Diarrhea: Adequate hydration, probiotics, bland diet
Constipation: Increase fiber intake, adequate fluids, light exercise

Clinical Safety Metrics

Good
Overall Safety Rating
8.2%
Discontinuation Rate
Research
Approved Status

CONTRAINDICATIONS

• Active cancer or history of malignancy (growth hormone may stimulate tumor growth)
• Severe cardiovascular disease or uncontrolled hypertension
• Uncontrolled diabetes mellitus or diabetic retinopathy
• Sleep apnea (untreated)

Medical Disclaimer

CJC-1295 is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Any use should occur only under medical supervision in approved research settings. Long-term effects are not well-studied in humans.